Medical Attributes of Cimicifuga racemosa - Black Cohosh

by April Kostick, Ashley Fauver, and Kristen Bohan
Wilkes University, Wilke-Barre, PA

July 2005

Cimicifuga racemosa, commonly the black cohosh, is a member of the buttercup family, Ranunculaceae (www.encyclopedia.com, 2005).  It is also known as bugbane, black root, rattle root, rattle top, rattle squawroot, rattle weed, and black snakeroot (Dumaine, 1991).  Black cohosh grows as a 3-8' tall perennial herb that is native to the eastern deciduous forests of North America, ranging from southern Ontario to Georgia, north to Wisconsin and West to Arkansas (Foster, 2000). Flowering stems are topped by a long plume of white flowers between June and September (Foster, 2000). The leaves are large and pinnately compound (Foster, 2000). The leaflets are irregularly shaped with toothed edges (Foster, 2000).

Cimicifuga racemosa
is a native North American and folk remedy that was introduced to the early settlers by the American Indians who used it for female ailments such as menstrual cramps, uterine spasms, fatigue, anxiety, rheumatoid arthritis, sore throat, and diarrhea.  It is used to help control hot flashes and vaginal dryness, also headache and depression associated with menopause (Greenbrook Farms Herbs & Such, 1998).  Black cohosh rhizomes and roots were routinely used to treat coughs, colds, constipation, fatigue, and rheumatism, as well as to increase breast milk production (Mahady et al., 2002). Korean folk medicine has widely used Cimicifuga racemosa as therapeutic for pain and inflammation (Kim, et.al. 2005).

Black cohosh contains several important ingredients that make it important medicinally (Foster, 2000).  Examples include triterpene glycosides (e.g. acetin and cimicifugoside), isoflavones (e.g. formononetin), aromatic acids, tannins, resins, fatty acids, starches, and sugars (Foster, 2000).

C. racemosa
has been found to be therapeutic in several different ways.  It has been found to be an alternative therapy for menopause as well as being used diaphoretic, antipyretic, antifungal, and antibacterial (Foster, 2000).   The safety of using black cohosh was also tested to determine whether it caused DNA damage, cancers, or allergies.

The active element formononetin binds to estrogen receptor sites inducing an estrogen-like activity in the body (Foster, 2000). Clinical studies in Germany have demonstrated that an alcohol extract of black cohosh decreases luteinizing hormone (LH) secretions in menopausal women (Foster, 2000).

A German study was performed to test the efficacy of black cohosh extract, commercially known as Remifemin, with that of conjugated estrogens for the treatment of climacteric symptoms and vaginal atrophy (Stoll, 1987).  Climacteric symptoms are characterized by physiological and psychic change at the end of the reproductive capacity of women and terminate with the completion of menopause (www.dictionary.com, 2005).  Vaginal atrophy is the diminution in the size of the cells in the vagina from their normal size (www.encyclopedia.com, 2005).  At the end of the 12 week treatment period, all groups showed improvements, in the group treated with the black cohosh, however, a significant decrease in climacteric symptoms was observed by a reduction in the Kupperman Index (KI) from 34 to 14, which indicates an improvement in vasomotor symptoms.  The group treated with black cohosh extract also showed a significant decrease in the Hamilton Anxiety Rating Scale (HAMA), and a significant improvement in the proliferative status of the vaginal epithelium, which indicates a possible estrogenic effect (Stoll, 1987).

In an open study, 50 women with climacteric symptoms, who had previously been treated with intramuscular injections of estradiol valerate and prasteronenantate, were alternatively treated with Remifemin extract.  Twenty-eight patients required no further injections, 21 patients required one injection in six months, and one patient required two injections.  The Kupperman Index decrease to below 15 points, indicating alleviation of symptoms (Petho, 1987).  Placebos were also used.
       
An open multicenter drug-monitoring study of 629 patients with menopausal symptoms assessed the efficacy of SBC-R extract at a dose of 80 mg daily for eight weeks of treatment.  Symptoms such as hot flashes, profuse sweating, headache, vertigo, nervousness, and depression were improved in more than 80% of all cases after six to eight weeks of treatment with the extract (Stolze, 1982).

Cimicifuga racemosa has been further examined to determine if it possesses health benefits in addition to aiding menopausal symptoms.  Methanol extracts were investigated for potential against menadione-induced DNA damage (Burdette, et al, 2002).  The extracts were observed to scavenge 1, 1-diphenyl-2-picrylhydrazyl (DPPH) free radicals (Burdette, et al, 2002).  The extracts also showed dose-dependent decreases in DNA single-stranded breaks and oxidized bases induced by the quinine menadione-using comet and fragment length associated repair enzyme assays (Burdette, et al, 2002).  Nine compounds showing antioxidant activity were subsequently isolated.  Six of these antioxidants were found to reduce menadione-induced DNA damage in cultured S30 breast cancer cells in their respective order of potency: methyl caffeate, caffeic acid, ferulic acid, cimiracemate, cimiraceamate, fukinolic acid (Burdette, et al, 2002).  On that basis the authors determined that black cohosh could protect against cellular DNA damage caused by reactive oxygen species by acting as antioxidants (Burdette, et al, 2002).

Supplements containing Cimicifuga racemosa were studied to determine the metabolism and possible toxicity of metabolites because they are so widely used by women (Johnson and van Breeman, 2003). After collecting urine samples from each of the women who participated in the study, a total of eight electrophillic metabolites of black cohosh were detected (Johnson and van Breeman, 2003). These included quinoid metabolites of fukinolic acid, fukiic acid, caffeic acid and cimiracemate B. Additional quinoid metabolites were formed from hydroxytosol and dihydroxyphenyl lactic acid neither of which had been previously isolated from black cohosh (Johnson and van Breeman, 2003). Mercapturate conjugates of these metabolites were not detected in urine samples from women who consumed single oral doses of up to 256mg of standardized black cohosh extract (Johnson and van Breeman, 2003).  This shows that moderate doses of a dietary supplement containing black cohosh shows no adverse reactions for the formation of quinoid metabolites in women (Johnson and van Breeman, 2003).

The safety of estrogen replacement for women with endometrial, ovarian, and breast cancers has been questioned after reports that estrogen stimulates proliferation of estrogen receptor positive tumors (Lancet, 1997).  In vitro studies of isopropanolic black cohosh extracts on estrogen-receptor positive breast cancer cell lines suggest that they do not stimulate cell proliferation (Bodinet, et al, 1999; Dixon-Shanies, et al, 1999; Freudenstein, et al, 1999).  The model used in this study was designed to evaluate the safety of black cohosh extracts for treatment of menopausal complaints with a history of breast cancer (Freudensein, et al, 2002). Mammary tumors were induced in Sprague Dawley rats. Doses of black cohosh were administered or controlled substances (placebo). Tumor number, size, plasma hormone levels, and weight of estrogen-sensitive organs were analyzed (Freudenstein, et al, 2002).  On that basis, the authors concluded that the black cohosh treatment did not stimulate cancerous growth (Freudenstein, et al, 2002).    

The potential effects of the extract on mast cell-dependant allergy reaction were tested using in vivo and in vitro models (Kim, et.al. 2005). In local lymph node assay the extract showed no potential of skin sensitization. The oral administration of the extract significantly inhibited the anti-IgE-induced passive cutaneous anaphylaxis reaction (Kim, et.al. 2005). There was also no inhibitory potential on the compound 48/80 induced histamine releases from peritoneal mast cells (Kim, et.al. 2005). These results demonstrate that the black cohosh has an anti-allergic potential and it may be due to the inhibition of histamine releases and cytokine gene expression in the mast cells (Kim, et.al. 2005).

Black cohosh can have adverse effects when not taken in the proper dosage.  Large dosages can cause abdominal pain, nausea, headaches, dizziness, symptoms of poisoning, and can also provoke miscarriage (Foster, 2000).  This herbal remedy has been also shown to cause the body’s immune system to launch an attack on the liver, known as autoimmune hepatitis.  Autoimmune hepatitis causes fatigue, abdominal discomfort, aching joints, and itching; without proper treatment the illness will progress and may be fatal (Laino, 2003). 

Black cohosh has been determined to be effective in several therapies.  One therapy where it has been successful is relief of menopausal symptoms, such as hot flashes and menstrual cramps in decreasing secretions of luteinizing hormones.  Other therapies that have shown positive results include anxiety and fatigue. Studies have also demonstrated that cancerous growth does not arise from Black cohosh.  Cimicifuga racemosa has anti-allergic potential and may prevent DNA cellular damage.  Black cohosh has been found in several studies to be both effective and safe, when the recommended dosages are taken. 



LITERATURE CITED:

Anonymous. 2005. http://www.dictionary.com.

Anonymous. 2005. http://www.encyclopedia.com.

Burdette, J.E., S.N. Chen, & Z.Z. Lu.  2002. Black cohosh (Cimicifuga racemosa L.) protects against menadione-induced DNA damage through scavenging of reactive oxygen species: bioassay-directed isolation and characterization of active principles. J Argic Food Chem. 50(24):7022-8.

Dasenbrook, C., J. Freudenstein, & T. NiBlein. 2002. Lack of promotion of estrogen-dependent mammary gland tumors in vivo by an isopropanolic Cimicifuga racemosa extract.  Cancer Research 62: 3448-3542.

Dumaine, S.E. 1991. Bugbane.  Horticulture 69.

Foster, S. 2000. Black cohosh; Cimicifuga racemosa.  The Steven Foster Group. Retrieved on July 12, 2005 from  http://www.stevenfoster.com/education/monograph/bkcohosh.html.

Greenbrook Farms Herbs & Such.  Herb Facts and Tips: Black Cohosh.  Retrieved June 29, 2005, from http://www.glenbrookfarm.com/herbs/blackcoh.htm.

Johnson, B.M. and R.B. van Breemen.  2003.  In vitro formation of quinoid metabolites of the dietary supplement Cimicifuga racemosa (black cohosh).  Chem. Res. Toxicol 7:838-46.

Kim, C.D., H.S. Cho, & M.H. Lee.  2004.  Inhibition of mast-cell dependent allergy reaction by extract of black cohosh (Cimicifuga racemosa).  Immunopharmacology and Immunotoxicology 26: 299-308.

Mahady, G.B. & D. Fabricant.  2002.  Black cohosh:  an alternative therapy for menopause?  Nutrition in Clinical Care 5: 283-289.

Petho A. 1987. Klimakterische Beschwerden. Umstellungeiner Hormonbehandlung auf ein pflanzliches Gynakologikum moglich?  Artliche Praxis. 38:1551-1553.

Stoll W. 1987. Phytopharmakon beeinflußt atrophisches Vaginalepithel Doppelblindversuch Cimicifuga vs. Ostrogenpraparat.  Therapeutikon.1:7-15.

Stolze H. 1982. Der andere Weg, klimakterische Beschwerden zu behandeln. Gyne.1:14-16.


This paper was developed as part of the BIO 368 - Medical Botany course offered at Wilkes University during the summer of 2005. Course instructor was Kenneth M. Klemow, Ph.D. (kklemow@wilkes.edu). The information contained herein is based on published sources, and is made available for academic purposes only. No warrantees, expressed or implied, are made about the medical usefulness or dangers associated with the plant species in question.

Return to Plant Summaries page


This page posted and maintained by Kenneth M. Klemow, Ph.D., Biology Department, Wilkes University, Wilkes-Barre, PA 18766. (570) 408-4758, kklemow@wilkes.edu.